Diffuse gliomas are the most common malignant brain tumors in adults, stratified by isocitrate dehydrogenase (IDH1/IDH2) mutation status. While the median age for central nervous system (CNS) World Health Organization (WHO) grade 2 to 3 IDH-mutant astrocytomas is 38 years, older patients of >55 years predominantly exhi...
Rasha Alfattal, Keng Lam, H. Ozkizilkaya et al.· International Journal of Sur...· 0 citations
The utility of ctDNA, particularly CSF ctDNA, as a complementary diagnostic tool in neuro-oncology is supported, with a promising performance of ctDNA analysis in patients with diffuse gliomas as a liquid biopsy strategy.
Christian Amezquita-Contreras, Angel Bueno, Diego Z. Arellano et al.· Neuro-Oncology Advances· 0 citations
The feasibility and validation of a two-day TAT NGS-based cfTNA assay that can potentially reduce time-to-treatment is reported that can potentially reduce time-to-treatment.
S. Roy-Chowdhuri, Ana Galán-Cobo, N. Agarwal et al.· Journal of Molecular Diagnos...· 0 citations
PIK3CA mutations are frequent drivers of metabolic reprogramming in BLCA, leading to increased glutamine flux, elevated OXPHOS activity, and enhanced fatty acid synthesis, all of which contribute to tumor progression.
K. R. Kami Reddy, V. Putluri, D. Piyarathna et al.· Cell communication and signa...· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.
